PMID: 9420064Jan 7, 1998Paper

Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy
S C PiscitelliR E Walker

Abstract

The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients.

References

Apr 1, 1978·Journal of Pharmacokinetics and Biopharmaceutics·K YamaokaT Uno
Mar 1, 1991·The Journal of Experimental Medicine·E P SampaioG Kaplan
May 1, 1991·British Journal of Haematology·D HeneyD L Barnard
Jan 1, 1974·International Journal of Dermatology·N Klüken, W Wente
Jun 1, 1995·AIDS·D SharpstoneB Gazzard
Jul 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·S MakonkawkeyoonG Kaplan
Jun 1, 1993·The Journal of Experimental Medicine·A L MoreiraG Kaplan
Feb 15, 1996·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·P J Weidle

❮ Previous
Next ❯

Citations

Sep 10, 1999·AIDS Research and Human Retroviruses·P A HaslettG Kaplan
Jan 24, 2004·The Journal of Pharmacy and Pharmacology·T ErikssonG A Kaysen
Jul 16, 2008·Expert Opinion on Drug Metabolism & Toxicology·Iris Breitkreutz, Kenneth C Anderson
Aug 10, 2002·Journal of Cellular and Molecular Medicine·S KumarS V Rajkumar
Mar 16, 2001·Expert Opinion on Pharmacotherapy·J M Jacobson
Nov 2, 2006·Biological & Pharmaceutical Bulletin·Rintaro KamikawaAyako Sasaki
Apr 15, 2004·Clinical Pharmacokinetics·Steve K TeoOscar L Laskin
Aug 29, 2002·Cancer Investigation·Said BaidasPankaj Bhargava
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Evangelos J Giamarellos-BourboulisHelen Giamarellou
Jun 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaji KumarS Vincent Rajkumar
Jun 12, 2001·Drugs·A Bousvaros, B Mueller
Jun 14, 2001·Journal of Clinical Pharmacology·S K TeoS D Thomas
Jul 14, 2005·European Journal of Drug Metabolism and Pharmacokinetics·Shufeng ZhouJames W Paxton
May 14, 2010·Revista Da Sociedade Brasileira De Medicina Tropical·Maria do Socorro da Silva Valente, José Luiz Fernandes Vieira
Aug 26, 2009·Therapeutic Drug Monitoring·José Luiz Fernandes Vieira, Maria do Socorro da Silva Valente
Nov 24, 2011·Cancer Chemotherapy and Pharmacology·Jodi A MuscalStacey L Berg
Oct 30, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Murali ChintagumpalaStacey L Berg
Oct 14, 2005·Expert Review of Anticancer Therapy·Shaji Kumar, S Vincent Rajkumar
Dec 4, 2004·Melanoma Research·André B ReirizGilberto Schwartsmann
Jan 31, 2002·Annual Review of Medicine·Paul RichardsonKenneth Anderson
Apr 13, 2002·Drugs & Aging·Shufeng ZhouJames W Paxton
Jan 6, 1999·Journal of Pharmaceutical Sciences·W D FiggE Reed
Nov 14, 2001·Dermatologic Clinics·J R LaDuca, A A Gaspari

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.